Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
CAI Orotate
2019 Nov 11
and does not significantly inhibit LRRK2 even at doses as high as 30 μM (500-fold higher than IC50 of inhibition of ROCK2)
trifluoromethyloxadiazole (TFMO)
33)30-12-10-29(11-13-30)24(31)21-15-28-22-7-6-19(26)14-20(22)23(21)17-2-4-18(5-3-17)25(16-27)8-9-25/h2-7
MK-1064 R501 CAI OrotateMK 1064 is a selective orexin 2 receptor antagonist (2 SORA) for the research of insomnia. target: 2 SORA In vivo: MK 1064 promotes sleep and increases both rapid eye movement (REM) and non REM (NREM) sleep in rats at OX2R occupancies higher than the range observed for dual orexin receptor antagonists. MK 1064 increases NREM and REM sleep in dogs without inducing cataplexy. The reference for animal administration is 30 mg kg. Product information CAS
US$ 361.50
US$ 176.50
US$ 195.50
US$ 325.00
US$ 648.50